Trial reportBlood advances2026
WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase 2 study.
Trial report in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractThis phase 2 clinical study evaluated the efficacy and safety of post-allogeneic hematopoietic stem cell transplantation maintenance cancer immunotherapy using 2 Wilms tumor 1 (WT1) peptide vaccines, MCI, for pediatric refractory acute leukemias. Each of 17 patients (median age, 8.3 years [range, 2-18]) was intradermally injected with either of the vaccines. The 3-year overall survival (OS) rate (primary end point) was 70.6% (95% confidence interval [CI], 43.1-86.6); this rate was >30%, a historical control benchmark, and was attributable to the fact that 12 clinical responders, who sustained complete remission at year 1 after the initiation of vaccination, had a high 3-year OS rate of 91.7% (95% CI, 53.9-98.7). WT1-specific cytotoxic T-cell (CTL) frequency in peripheral blood (PB) from all 12 clinical responders increased significantly after vaccination, reaching the maximum by week 12 of vaccination (before, 0.25% ± 0.08%; after, 1.07% ± 0.24%; P< .001), whereas WT1-specific CTL frequency in PB from clinical nonresponders remained unchanged after vaccination (before, 0.12% ± 0.2%; after, 0.20% ± 0.25%; P = .424). The estimated 3-year OS rate was significantly higher for 11 immune responders (who showed a ≥1.455-fold increase from the baseline value: 90.9%) than for 5 immune nonresponders (40.0%; P = .027). Elevated WT1-specific CTL frequency in the PB before vaccination predicted the subsequent favorable patient prognosis. No patient discontinued treatment because of MCI. Adverse events including graft-versus-host disease were manageable. MCI was suggested to be very effective and safe for pediatric patients with refractory acute leukemias, indicating its potential to improve their survival through relapse prevention. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry as #UMIN000005319.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.